Mounjaro not working or a weight plateau: the quick answer
If Mounjaro is not moving the scale, it does not automatically mean that it has stopped working. The main things to review are: an early treatment stage or missed doses; water retention, constipation or inconsistent weighing; more food or energy-containing drinks than expected, or intake so low that movement and protein suffer; sleep and stress; another medicine or a health issue such as thyroid disease, PCOS or insulin resistance; and a storage or injection-use error. Track a trend rather than one day, and see the clinician before any treatment change.
There is an important difference between no clear loss in the early weeks and a plateau after previous loss. In studies, some people with a slower early response later achieved clearer loss; that does not promise an outcome for any individual or replace follow-up. A plateau is a sustained flat trend after loss and calls for a joint review of measurements, food, movement, sleep, medicines and use. Do not increase the dose yourself, bring injections closer together, count pen clicks or try to extract an extra amount from a pen: these are unsafe and outside the instructions for use. See the Mounjaro pen use, storage and missed-dose guide if storage or injection is in doubt, and the visceral fat, waist and InBody guide to understand the difference between scale weight and body composition [1, 3, 10, 11].
Is Mounjaro not working, or is the scale temporarily quiet? Define the problem first
When someone says “Mounjaro is not working,” they may mean one of three different patterns: weight never moved, it fell and then levelled off, or it is moving more slowly than expected. That distinction matters because each pattern needs a different review. One flat reading is not enough. Fluid, salt, constipation, measurement time and gut contents can conceal fat change for days. Look at a trend across several weeks under comparable conditions, not the lowest number that appeared on the scale [1, 5, 11].
Treatment stage also matters. The original SURMOUNT-1 trial followed tirzepatide with eating and activity support over a long period; it was not a rapid test after one or two injections. In a later analysis, 18% of participants had lost less than 5% at week 12. Among that later-response group, 70% reached at least 5% loss by week 24 and 90% did so by week 72. It shows that a slow early response is not automatically a final verdict [1, 2].
A sustained flat trend still deserves a structured review rather than dismissal. Record baseline weight, the current average, waist, the clinician-prescribed dose history, missed doses, and adverse effects that changed food or fluid intake. The Mounjaro results-timeline article explains response timing in detail; this guide focuses on sorting the reasons for slower progress [1, 2, 4].
Dose stage and use: review them without increasing it yourself
Tirzepatide is used within a clinician-directed plan. Its starting dose is intended for treatment initiation rather than maintenance. The official prescribing information sets out an escalation schedule and limits, while dose selection depends on response and tolerability. If you are still at the beginning, had an interruption or missed doses, comparing your result with someone who has remained on a maintenance dose for months will be misleading [3].
A practical review starts with simple questions. Did you use the pen or vial prescribed for you? Was the weekly day consistent? Were there missed doses or gaps? Was it stored according to its instructions and the guide on how to use the Mounjaro pen? Did vomiting, diarrhoea or very low intake make the plan difficult to continue? Bring the pack, or a clear photograph of its label, and a list of dates to the appointment. A brand name alone does not confirm the concentration or how it was used [3, 11].
Do not increase the dose, bring injections closer together or combine doses because the scale is flat. Self-escalation may increase adverse effects and will not correct a cause such as fluid change, unnoticed eating or another weight-promoting medicine. NICE places review of lower response to tirzepatide in the context of the highest tolerated dose and adequate time on it. That decision belongs to the clinician after balancing benefit and tolerability, not to one week's number [3, 4].
Review eating without blame: less hunger does not always mean less energy intake
Tirzepatide can reduce appetite and support fullness, but it does not cancel the effect of an eating pattern. Someone may eat smaller meals yet compensate through frequent grazing, energy-containing drinks, sauces, late-night eating or larger meals on days when appetite feels better. This is not proof of weak willpower. Appetite, behaviour and environment interact, and after weight loss the body may oppose further loss through changes in hunger and energy expenditure [2, 5, 11].
Instead of severe restriction, record meal times, hunger before meals, fullness afterwards, drinks and grazing for one or two weeks without trying to make the record look ideal. Check whether nausea led to very little daytime intake followed by compensatory evening eating, or whether reliance on easy-to-eat foods displaced protein and fibre. The purpose is to reveal a pattern that can be adjusted safely, not to turn every day into an arithmetic test or deprivation [5, 11].
Activity is also more than planned exercise. Fatigue, pain or desk work may reduce spontaneous daily movement even when a workout remains unchanged. As body weight falls, energy needs may also be lower than at baseline. Review food, everyday movement, resistance exercise, function and sleep together. Do not impose a severe intake cut on yourself; inadequate nutrition can worsen weakness and undermine preservation of fat-free mass [5, 10, 11]. If a smaller appetite shrinks your meals, keep protein in each one; see these high-protein foods for weight loss.
Sleep and recovery: relevant, but rarely the only explanation
Short sleep can make hunger harder to manage, create more opportunities to eat during waking hours and reduce energy for movement. In a small randomized trial during energy restriction, reducing sleep by about one hour on five nights each week altered the proportion of lost weight that came from fat, even though total weight loss was similar between groups. The study was small and did not involve tirzepatide. It shows that recovery and the quality of loss may be affected; it does not mean that one poor night stops the medicine [6].
Review average sleep across two weeks, timing, repeated waking, loud snoring, witnessed breathing pauses and daytime sleepiness. Do not reduce the answer to “sleep more” when there are signs of sleep apnoea or persistent insomnia; those patterns need appropriate assessment. Equally, do not blame sleep alone before reviewing measurement, dosing, eating, movement, medicines and health conditions [5, 6].
A useful step is to keep wake time reasonably consistent, reduce unplanned eating during late waking hours and record how sleep relates to hunger and energy rather than changing ten things at once. The dedicated sleep-and-plateau article explains a structured trial and signs that merit sleep assessment. Here, sleep belongs on the review list as one part of the picture, not a ready-made diagnosis [5, 6].
Other medicines may oppose the trend: review them, but do not stop treatment
Some prescribed medicines can be associated with weight gain, fluid retention or increased appetite in some people. Medical reviews list classes including certain antipsychotics and antidepressants, corticosteroids, insulin and some other diabetes treatments, and some neurological or allergy medicines. Effects differ within each class, and not everyone has the same response [7].
Timing helps. Did the plateau start after a new medicine or dose change? Was there rapid swelling rather than gradual gain? Did treatment increase sleepiness, hunger, thirst or eating intended to prevent low glucose? List every prescription, non-prescription product and supplement with its start date. A complete list is more useful than trying to select one culprit from memory [7, 11].
Do not stop insulin, psychiatric medicine, a corticosteroid or any chronic treatment because of the scale. Abrupt withdrawal can be dangerous, and the medicine may be essential for a condition more urgent than weight. The clinician can assess whether the link is plausible, whether a suitable alternative exists, and whether timing or monitoring can change without undermining treatment of the original illness. The dedicated article on medicine-related weight gain explains those steps in greater depth [7].
Thyroid and other medical causes: test when clues exist, not by guesswork
Hypothyroidism can contribute to weight gain and difficulty losing weight, but fatigue and gain are common symptoms and do not confirm the diagnosis. Clues such as cold intolerance, constipation, dry skin, a slower pulse or a thyroid history make the clinical discussion more focused. Diagnosis uses history, examination and thyroid blood tests. It commonly starts with TSH interpreted with free T4 and the clinical context, not symptoms alone [8, 9].
If you already take levothyroxine, do not increase thyroid hormone for weight loss. Review adherence, dose timing, interactions and test results with the clinician. Thyroid hormone treats confirmed deficiency; using excess hormone to chase weight can harm the heart, bones and muscles. Because the hypothyroidism-and-weight article covers diagnosis and treatment, this article keeps thyroid disease on the list of causes to investigate when clues support it [8, 9].
The clinician may broaden the review according to the individual: poorly controlled glucose, fluid retention, pain that restricts movement, symptoms of depression or binge eating, or signs of another endocrine condition. There is no single “plateau blood panel” for everyone. Testing should be directed by history and examination so that a normal slowing is not turned into a diagnosis and a genuine clue is not missed [8, 9, 11].
Weight is not only fat: separate fat, lean tissue, fluid and measurement error
The scale combines fat, fat-free tissue, water and gut contents in one number. Waist may improve slowly while weight appears flat, or the reverse. A SURMOUNT-1 body-composition substudy included 160 participants and found that loss with tirzepatide contained both fat and lean mass. On average, about three quarters of lost weight was fat mass and one quarter was lean mass. That is an average from a small substudy, and the ratio varies from person to person [10].
Body-composition devices provide estimates affected by hydration, meal timing, exercise and measurement conditions. Do not compare a reading taken after exercise in hot weather with an early-morning reading under different conditions, or treat one day's change as proven muscle gain or fat loss. Keep the device, time and conditions as consistent as practical, and measure waist at the same location using the same method [10].
Also follow strength, function, adequate protein and food intake, and symptoms of weakness. If weight is falling but strength is deteriorating quickly or eating has become nearly impossible, the goal is not to push the scale harder; tolerability and nutrition need review. If weight is flat while a reliably measured waist and function improve, that differs from every indicator being unchanged. The visceral-fat, waist and InBody guide explains how to read a trend without accepting one device as a diagnosis [10, 11].
When should you seek review, and what needs faster action?
Arrange a review when weight and waist trends have not moved after adequate time for your plan, weight has begun to rise again, or adverse effects prevent normal eating and drinking. NICE identifies a decision point when less than 5% of baseline weight has been lost after six months on the highest tolerated dose: reasons and the balance of continuing treatment should then be discussed with the clinician. This is not an instruction to reach a particular dose yourself, and it is not a rule for stopping without assessment [4].
Bring a simple record: weights under comparable conditions, waist, actual dose dates, adverse effects, sleep, a short food log, activity, and every medicine and supplement. A useful review asks in order: is the plateau real; have time and treatment stage been adequate; has the medicine been used as prescribed; is eating, sleep or movement contributing; and does another medicine or health condition need attention? Only then can the clinician decide whether the plan should continue, change or move to a different pathway [1, 3, 4, 11].
Seek urgent care for severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, signs of dehydration or fainting, breathing difficulty, sudden severe swelling, or symptoms of severe low glucose, particularly when other diabetes medicines are used. Seek immediate help for thoughts of self-harm or an acute eating disorder crisis. For a follow-up with a weight-management doctor at the Maadi branch, or at Fifth Settlement where weight management is available, contact the clinic on WhatsApp. A structured review does not promise an outcome or mean an automatic dose change [3, 11].
